KZIA Kazia Therapeutics Limited
USHealthcareAs of 2026-07-10 16:00
Why KZIA matters now
Kazia Therapeutics Limited (KZIA) is a US stock in Healthcare. The latest InvestLog snapshot shows $13.56 with +4.47% on the session and $22.0M in market capitalization; recent performance reads 1-month +14.74% and YTD +101.16%.
The latest financial table shown here is Q2 2026, with revenue of $0.00, net income of $-12.3M, and EPS of $-3.95. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -28.4%.
The latest indexable market news headline is "Kazia Therapeutics Appoints James Levine as Chief Financial Officer" from PRNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $28.50; recent insider activity includes Levine James E. filing . These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
1.33
P/S
1623.57
EV/EBITDA
2.05
DCF Value
$-0.59
FCF Yield
-28.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
100.0%
Operating Margin
-92086.4%
Net Margin
-113004.6%
ROE
-116.9%
ROA
-31.4%
ROIC
-36.2%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $0.00 | $-12.3M | $-3.95 |
| Q4 2025 | $19.7K | $-10.0M | $-6.40 |
| FY 2025 | $42.0K | $-20.7M | $-18.90 |
| Q2 2025 | $22.3K | $-10.5M | $-6.15 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$28.50
Target (Median)
$28.50
Target Range
$25.00 - $32.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
AU
Exchange
—
Beta
2.18
Kazia Therapeutics Limited is a biotechnology firm primarily dedicated to creating pharmaceutical treatments for cancer. Its leading therapeutic asset is Paxalisib, a distinctive small molecule that can penetrate the brain and works by inhibiting the PI3K/Akt/mTor pathway, showing promise as a potential remedy for glioblastoma. The company is also progressing with EVT801, an experimental medication being investigated for its efficacy against various cancer types. Incorporated in 1994, the entity operated under the name Novogen Limited until its rebranding to Kazia Therapeutics Limited in November 2017. The company's main operations are based in Sydney, Australia.